CN113181206B - 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 - Google Patents
与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 Download PDFInfo
- Publication number
- CN113181206B CN113181206B CN202110483204.5A CN202110483204A CN113181206B CN 113181206 B CN113181206 B CN 113181206B CN 202110483204 A CN202110483204 A CN 202110483204A CN 113181206 B CN113181206 B CN 113181206B
- Authority
- CN
- China
- Prior art keywords
- group
- sirna
- slc2a9
- gene
- uric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 39
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 20
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 12
- 108091006303 SLC2A9 Proteins 0.000 title abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 101150068737 SLC2A9 gene Proteins 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 6
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 101710104287 Solute carrier family 2, facilitated glucose transporter member 9 Proteins 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108091081021 Sense strand Proteins 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 58
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 54
- 229940116269 uric acid Drugs 0.000 abstract description 54
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 13
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract description 11
- 230000009368 gene silencing by RNA Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000009103 reabsorption Effects 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 238000001415 gene therapy Methods 0.000 abstract description 3
- 238000003197 gene knockdown Methods 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 29
- 210000000813 small intestine Anatomy 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 238000001890 transfection Methods 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 210000003405 ileum Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000000231 kidney cortex Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012096 transfection reagent Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- -1 T-CHO Chemical compound 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 102100032421 Protein S100-A6 Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023435 Kidney small Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于基因治疗的药物技术领域，具体涉及与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用。本发明利用SLC2A9基因在肾小管和小肠管腔细胞中的作用，进一步利用RNA干扰(interference,RNAi)方法，构建了SLC2A9基因小分子干扰RNA，即siRNA，敲低SLC2A9基因的表达，减少尿酸在肾小管和小肠管腔的重吸收，达到降低血尿酸的目的。
Description
技术领域
本发明属于基因治疗的药物技术领域，具体涉及与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用。
背景技术
随着物质生活水平的提高，人们的饮食模式也在发生改变，高嘌呤、高脂肪高蛋白、高糖食物的过量摄入使原发性高尿酸血症伴高血脂、高血糖，体重增加等代谢性疾病发病率逐年增长，已经成为危害人们健康的重要因素。尿酸、糖和脂代谢互为因果，相互影响，共同影响血脂、血糖和血清尿酸的水平。当血清尿酸超过402μmol/L后，尿酸盐容易形成尿酸盐结晶，沉积在关节皮下等，而引起痛风发作，病人疼痛不堪，严重危害人们生理和心理健康。欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism)规定：痛风患者血清尿酸(SUA)水平应维持在5-6mg/dL(300-360μmmol/L)。
目前，市场上治疗高尿酸血症的西药种类繁多，EULAR也推荐了11种经典药物，但是这些药物都是化学合成的，肝肾毒性和破坏肠道等副作用大，降低了疗效，甚至给病人带来其他的不适。因此，需要发明一种既能降尿酸，副作用又少的治疗方法。
RNA干扰(RNA interference，RNAi)是指基因治疗的一种，将序列特异性的同源双链RNA(small interference RNA,siRNA)导入到细胞或者动物体内，识别并靶向降解同源mRNA，使目的基因的不表达或者表达降低。RNAi技术当前作为一种具有革命性的基因转录后调控新技术，由于其特有的高效性和特异性，不仅成为基因功能研究的有力工具，还为疾病的靶向治疗治疗提供了新的技术手段和应用前景。
发明内容
根据现有技术上存在的缺陷，结合目前的研究前沿，本发明提供了与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用。
本发明是采用以下的技术方案实现的：
本发明提供了抑制GLUT-9蛋白表达的核酸物质在开发治疗高尿酸血症伴高血脂、高血糖的药品中的应用。
具体的，所述抑制GLUT-9蛋白表达的核酸物质为抑制SLC2A9基因表达的siRNA。
其中，所述siRNA由体外合成的正义链和反义链碱基配对退火形成；siRNA的正义链的核苷酸序列为SEQ ID NO:1，反义链的核苷酸序列为SEQ ID NO:2。
本发明还提供一种siRNA，其为上述任一项所述抑制SLC2A9基因表达的siRNA。
本发明的核心在于，用RNA干扰(interference,RNAi)方法，敲低SLC2A9基因的表达，减少糖尿酸在肾小管和小肠管腔的重吸收，最终通过调控糖蛋白质脂肪代谢，达到降低血尿酸，降低血脂血糖的控制体重的目的。根据SLC2A9基因mRNA序列和RNA干扰原理，设计三对双链小干扰RNA分别是SiRNA-1、SiRNA-2、SiRNA-3序列见表2；与小鼠mRNA无任何同源性的错义SCR siRNA(scramble-siRNA)为(Negative Control,NC)，序列见表2，即在体外(细胞水平)筛选鉴定敲减效果最好的，用敲减效果最好的SiRNA做体外实验(动物实验)。
与现有技术相比，本发明的有益效果：
SLC2A9基因编码糖转运蛋白9(GLUT-9)，在肾小管上皮细胞和小肠上皮细胞等表达，在葡萄糖和尿酸从肾小管管腔和肠腔重吸收到细胞内发挥重要作用。SLC2A9基因表达增加可以促进管腔内的葡萄糖、尿酸重吸收增多，使血尿酸和血糖增高，SLC2A9基因表达降低可以减少管腔内的尿酸重吸收，特别是减少肠道对糖的吸收，尿酸排出增加，使血尿酸血糖血脂降低。将RNA干扰技术应用于SLC2A9基因，靶向抑制SLC2A9基因的表达治疗以调节尿酸增高伴血糖血脂代谢异常提供治疗思路和方法。本发明提出的siRNA序列可作为一个降低血尿酸血糖血脂的备选思路方法，减少研发新药的成本、时间及风险，为我国医药事业发展节省资源。
附图说明
根据本文给出的发明详述和伴随的附图，将更全面地理解本发明，这些发明详述和附图仅以说明的方式给出，而不限制预期的发明范围。
图1为实施例1中靶向SLC2A9基因siRNAs设计的初步结果；
图2为实施例1中RNAStructure4.5软件预测SLC2A9的mRNA局部二级结构与三个SiRNA匹配结果；
图3为实施例2中以TCMK1为靶细胞，5分组利用RT-PCR检测SLC2A9的mRNA转录量对比图；
图4为实施例2中以TCMK1为靶细胞，5分组利用Western blots检测SLC2A9蛋白表达量对比图，β-actin为内部参照；
图5为实施例3中UAG组TCMK1细胞内尿酸浓度随时间变化的对比图,在24小时时段浓度达最高，与BCG组相比，P<0.05；
图6为实施例3中TCMK1细胞内、外的尿酸浓度对比图，与空白对照组、MG和SCR组相比，SiSLCA9有显著抑制尿酸吸收作用P<0.05；
图7为实施例4、5中KM雄性小鼠3分组的0、4、6、8周SUA变化结果；
图8为实施例4、5中KM雄性小鼠3分组的0、4、6、8周UUA变化结果；
图9为实施例4、5中KM雄性小鼠3分组的0、4、6、8周TG变化结果；
图10为实施例4、5中KM雄性小鼠3分组的0、4、6、8周T-CHO变化结果；
图11为实施例4、5中KM雄性小鼠3分组的0、4、6、8周Glu变化结果；
图12为实施例4、5中KM雄性小鼠3分组的0、4、6、8周Weight变化结果；
图13为实施例6中第8周KM雄性小鼠3分组的血清肌酐Cr的含量图13(A)、血尿素氮BUN的含量图13(B)；黄嘌呤氧化酶XOD的变化图13(C)；
图14为实施例6中第8周KM雄性小鼠3分组的肾脏皮质(图14(A))和小肠回肠(图14(B))用ELISAI方法检测促炎因子L-1β的变化图；
图15为实施例6中第8周KM雄性小鼠3分组的小肠内容物尿酸的变化图；
图16为实施例6中第8周KM雄性小鼠3分组的肾脏皮质(图16(A))和小肠回肠(图16(B))的HE染色免疫组化图；
图17为实施例6中第8周KM雄性小鼠3分组的肾脏皮质(图17(A))和小肠回肠(图17(B))的免疫组化GLUT-9蛋白质的表达变化图。
具体实施方式
为了使本发明目的、技术方案更加清楚明白，下面结合附图，对本发明作进一步详细说明。下述实施例中所述实验方法，如无特殊说明，均为常规方法；实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件或者按照产品说明书进行；所述试剂和材料，如无特殊说明，均可从商业途径获得。
1、下列实施例采用的材料如下：
小鼠肾小管上皮细胞(TCMK1)，待融合率80-90％时1:3传代。
TCMK1细胞培养基溶液：体积比为87％DMEM,高糖+12％FBS+1％双抗。FBS:胎牛血清，购自公司大连美仑生物技术有限公司，货号PWL001；双抗:100U/ml青霉素/链霉素溶液，购自公司，货号；DMEM,高糖，购自Thermo FisherScientific公司，货号11965118)
RNA转染试剂EntransterTM-R4000：购自英格恩生物公司，货号4000-3。
RNA转染试剂EntransterTM-in vivo：购自英格恩生物公司，货号18668-11-1。
高血尿酸颗粒饲料，配制按质量分数比例为：10％酵母粉(OXOID；LP0021)+10％果糖(Macklin；F875004)+20％五花肉+60％基础饲料(济南朋悦实验动物繁育有限公司)。
基础饲料，购自济南朋悦实验动物繁育有限公司，普通环境实验鼠饲料。
尿尿酸UUA、血清尿酸SUA、甘油三酯TG、总胆固醇T-CHO、血清肌酐Cr、操血尿素氮BUN检测试剂盒：Uric acid(UA)Test Kit(Enzyme Colorimetry)、Triglyceride assaykit(GPO-PAP enzymatic method)、Total cholesterol assay kit(Single reagent GPO-PAP method)、Creatinine(Cr)Assay kit(sarcosine oxidase)、Urea Assay Kit和denosine deaminase assay kit(Enzyme colorimetry)，以上试剂盒均购自南京建成生物工程公司，货号C012-2-1、A110-1-1、A111-2-1、C011-2-1、C013-2-1、A048-2-1，所有操作按照试剂盒说明进行。
血糖Glu检测试剂盒：Glucose assay kit(Glucose oxidase method；Rsbio.com)，所有操作按照试剂盒说明进行。
小鼠IL-1βELISA试剂盒：购自Liankebio公司，目录号70-EK201B/3-96。
2、实验过程
细胞外RNA转染操作：
(A)体外转染操作：(1)取0.67μg(50pmol)的siRNA，加入一定量无血清DMEM稀释，充分混匀，制成RNA稀释液，终体积为25μl。(2)取1μl的EntransterTM-R4000,然后加入24μl无血清稀释液体,充分混匀,制成EntransterTM-R4000稀释液,终体积为25μl。室温静置5分钟。(3)将EntransterTM-R4000稀释液和RNA稀释液用振荡器振荡充分混合,室温静置15分钟。转染复合物制备完成。(4)将50μl转染复合物滴加到有0.45ml全培养基(可含10％血清和抗生素)的细胞上,前后移动培养皿,混合均匀。(5)转染后6小时观察细胞状态,如状态良好可不必更换培养基,继续培养48小时，裂解细胞，提取RNA和蛋白质，做Real-time PCR和Western blotting，得结果。
(B)体内转染操作：EntransterTM-in vivo的用量。SiRNA(μg)和EntransterTM-invivo(μl)按照1:2的比例使用下面以12.5μg的核酸与25μl转染试剂,总注射体积100μl,20g小鼠尾静脉注射为例说明。(1)核酸的稀释。将12.5μg核酸用适量无内毒素纯水稀释成1μg/μl(如核酸原液浓度小,注射体积会增大),加入12.5μl的水,再加入10％葡萄糖溶液(w/v)25μl,终体积50μl,充分混匀。(2)转染试剂的稀释。取25μl的EntransterTM-in vivo试剂用25μl的10％葡萄糖溶液稀释,终体积为50μl,充分混匀。(3)转染复合物形成。在室温将稀释后的转染试剂加入到稀释后的核酸溶液中,充分混匀。(4)室温静置15分钟。配制好的转染复合物请即配即用,不宜长期存放。
Real-time PCR操作：用TRIzol(Sigma)裂解细胞，用异丙醇RNA提取，然后由乙醇沉淀。使用1μg RNA逆转录得第一链cDNA(南京Vazyme)。根据
III RT SuperMix的qPCR(南京Vazyme)试剂盒说明书配制PCR反应体系为：用2μl的cDNA产物进行20μl的终体积反应，其中含有2×ChamQ-SYBR-Color-qPCR-Master混合物10μl(Vazyme)、0.4μl的正、反义引物、ddH2O 7.2μl。基因表达值标准化用内参照管家基因GAPDH。用于PCR的基因特异性引物序列和所用反应条件如表1所示。
表1、SLC2A9基因的RT PCR特异性引物序列和所用反应条件表
Western blots操作：用RIPA(Solarbio)裂解细胞，提取蛋白。用15μg蛋白质进行蛋白质印迹(Western blotting)。简单地说，电泳并转移到PVDF印迹膜中，将膜在5％脱脂奶粉中封闭1h，然后在4℃下与兔抗人SLC2A9/GLUT9(1:1000；Millipore)孵育过夜。与辣根酶标记的山羊抗兔抗体(Zsbio)孵育40min，通过化学发光方法检测条带，Image-pro plus8.软件计算灰度值。β-actin为内参照蛋白。
肝匀浆检测黄嘌呤氧化酶XOD操作：处死小鼠，迅速取出肝脏样本，置冰上，与生理盐水1:9混合,匀浆。匀浆液在4℃条件下12,000r/min离心10min,取上清液,上清液在4℃条件下继续以12,000r/min离心10min,取上清液用Xanthine Oxidase(XOD)assay kit(Colorimetric method)试剂盒(南京建成生物工程公司,A002-1-1)测定小鼠肝脏黄嘌呤氧化酶活性，操作按照试剂盒说明进行。
促炎因子IL-1β检测ELISAI操作：
处死小鼠，迅速取出肾皮质和小肠回肠部分，做匀浆，取上清，方法同肝匀浆。采用酶联免疫吸附试验(ELISA)方法检测肾皮质和回肠中IL-1β的含量：
基本步骤如下：
(1).包被：用碳酸盐包被缓冲液将抗体稀释至蛋白质含量为1-10μg/ml。在聚苯乙烯酶标板的每孔加100μl，4℃过夜。次日，弃去孔内溶液，用洗涤缓冲液洗3次，每次3min。(一般商品化的试剂盒中已包被好抗体，此步骤可省略)
(2).封闭：每孔加入200μl封闭液，37℃孵育1-2h。
(3).洗涤：小心揭掉封板膜，放入洗板机，洗涤3-5遍。也可以手动洗板：弃去液体，每孔加入300μl洗液，浸泡1-2min，在吸水纸上拍干，重复3-5遍。(一般商品化的试剂盒中已包被好抗体，前三个步骤可省略)
(4).加样：加适当稀释的待检样品100μl于上述已包被的反应孔中。(同时做空白孔，倍比稀释的标准品孔，有条件可加做阴性对照孔及阳性对照孔作为质控点)。
(5).温育：用封板膜封板后置37℃孵育1-2h。
(6).洗涤：同步骤3。
(7).加抗体：于各孔中加稀释好的生物素化抗体工作液100μl。
(8).温育：用封板膜封板后置37℃孵育1h。
(9).洗涤：同步骤3。
(10).加酶结合物：于各孔中加稀释好的酶结合物工作液100μl。
(11).温育：用封板膜封板后置37℃避光孵育30min。
(12).洗涤：同步骤3。
(13).加显色底物：于各孔中加入TMB底物溶液100μl，37℃避光反应10～30min，直到倍比稀释的标准品孔出现明显的颜色梯度为止。
(14).终止反应：于各反应孔中加入2M硫酸100μl，颜色由蓝色变为黄色。
(15).结果测定：10min内，在酶标仪上，于450nm处，以空白对照孔调零后测各孔OD值。
全小肠内容物尿酸含量检测：实验结束前一晚禁食，处死各组小鼠，立即切除全部小肠(从十二指肠上端到回肠下端)。然后将其放在无菌台上，纵向切开，尽可能刮除所有肠道内容物，4℃条件下12,000r/min离心10min,取上清液,上清液在4℃条件下继续以12,000r/min离心10min。取上清液测定尿酸的方法与先前上述。
HE染色免疫组化：
(A)HE染色：处死各组小鼠，取肾皮质和回肠组织，用4％多聚甲醛固定，经浸蜡包埋,切片(4μm)与贴片,脱蜡,HE染色,脱水透明,封片，显微镜观察，扫描或拍照。
(B)免疫组化：取小鼠肾皮质和回肠组织4μm石蜡切片，用抗GLUT9(1:2000)的多克隆抗体，通过与生物素标记的抗体(1:200，37℃1h)和辣根过氧化物酶标记的链霉亲和素(1:200，37℃1h)的反应，鉴定了免疫反应性，显微镜观察，扫描或拍照。
3、KM雄性小鼠分组
4周龄KM雄性小鼠在12：12小时白昼晚上交替，室温状况下喂养，适应性喂养1周，自由饮食。模拟人的不健康的高嘌呤、高糖、高脂和高蛋白生活习惯制备模型饲料：按质量分数10％酵母粉+10％果糖+20％含猪五花肉+60％基础饲料。实验分组为三组：
正常饲料对照组(a blank control group，BCG)：基础饲料饮食；
高尿酸模型饲料组(a hyperuricemia model group，MG)：模型饲料饮食；
SiSLC2A9组(SiSLC2A9)：1-4周模型饲料饮食，4-8周模型饲料饮食+SiSLC2A9尾静脉注射(注射量1.3mg/kg每3天一次)。
4、统计
所有实验数据均用SPSS Statistics.26软件计算，经邦佛伦尼矫正和T-test,用mean±SD表示。统计的显著性用单因素方差分析两两比较(组间比较)和多因素方差分析两两比较(组间比较和组内比较)确定，统计显著性为P<0.05.显著性用字母标记法标记：如果组间比较或者组内比较有相同的字母(或符号)，意味着没有显著性差异；如果没有相同的字母(或符号)，意味着有显著性差异。
实施例1、靶向SLC2A9基因的siRNA的设计
在NCBI：https://www.ncbi.nlm.nih.gov/网站的Gene模块中获取Mus musculussolute carrier family 2(facilitated glucose transporter),member 9(Slc2a9),transcript variant 1,mRNA,(No.NM_001102414.1)mRNA的全长序列，用BLOCK-iTTM RNAiDesigner在线设计软件，在Accession number输入No.NM_001102414.1；选择Open readingframe(ORF)作为同源干扰靶点；Minimum G/C percentage为35％，Maximum G/Cpercentage为60％；用Mouse-Mus musculus database进行同源基因序列BLAST的比对排除。结果如图1所示。
随后对上述经初步设计得到的10条siRNA序列进行验证。用SiRNA在线设计网站http://sidirect2.rnai.jp/design.cgi和http://biodev.extra.cea.fr/DSIR/DSIR.html分别设计验证，发现用上述三个SiRNA设计软件，在SLC2A9基因的开放阅读框架(ORF)里,在670-695、1100-1125和1234-1248三个位点都有抑制作用：软件设计的siRNA的是DNA的碱基A、G、C、T,根据以DNA为模板，转录生成RNA碱基A、G、C、U的配对原则，将DNA序列中的T转换成U。用RNAStructure4.5软件预测SLC2A9的mRNA二级结构，避开复杂二级结构，局部二级结构与SiRNA匹配如图2。
SCR为错义siRNA(scramble-siRNA)，即与小鼠mRNA无任何同源性的乱序的siRNA作为阴性对照。以上siRNA序列由上海吉玛生物有限公司对进行化学合成，最终设计的靶向SLC2A9基因siRNA序列见表2。
表2、SCR siRNA序列和三对SLC2A9基因的SiRNA双链碱基序列
实施例2、SiRNAs筛选
实验分组为5组，空白对照组(Blank Control Group，BC)；SCRNA阴性对照组(ScRNA Negative Control，SCR)；SiRNA-1组(SiRNA-1),SiRNA-2组(SiRNA-2),SiRNA-3组(SiRNA-3)，用RNA转染试剂进行基因递送，转染后48小时提取TCMK1细胞的总RNA和蛋白质，做Real-time PCR和Western blots检验，结果见图3、图4。
结果显示：Q-PCR统计分析、WB条带灰度分析，SiRNA-2，在mRNA和蛋白水平表达显著下调作用，SiRNA-2命名为SiSLC2A9进行后续实验。
实施例3、细胞水平沉默效果验证——尿酸刺激和尿酸吸收实验
(1)尿酸刺激(目的是确定尿酸能不能进入TCMK1细胞和进入细胞后细胞内的尿酸浓度达最高时间)
用含400μmol/L尿酸的正常培养基，培养TCMK1细胞(空白对照组BCG)0、6、12、24、48h后，Heat-Shock法裂解细胞，测细胞内尿酸浓度，结果显示在24h时段，细胞内尿酸浓度最高见图5，其中UAG为尿酸组(Uric Acid Group，UAG)，取细胞外培养基，作为外部参照。
空白对照组BCG目的是作为对照，观察UAG组(尿酸组)细胞，尿酸是否进入细胞，和进入细胞的时间与浓度的变化，为以下的尿酸吸收实验确定尿酸能进入细胞和在24小时时段测尿酸吸收与否的依据。
(2)尿酸吸收实验
TCMK1细胞分为4个实验组分别为：正常培养基培养组(Normal Control Group，NCG)；尿酸组(Uric Acid Group，UAG)：用含400μmol/L尿酸的培养基培养TCMK1细胞；SCR组：含400μmol/L尿酸的培养基培养+SCR siRNA转染(SiRNA的终浓度为100nM,SiRNA:R4000(100pmol 1:2μL)；SiSLC2A9组：用含400μmol/L尿酸的培养基培养+SiSLC2A9转染。转染24h后，分别取细胞外培养基和裂解细胞，测细胞内外尿酸浓度的变化，结果如图6所示。结果显示SiSLC2A9组细胞外尿酸浓度显著高于MG组和SCR组，说明SiSLC2A9有显著的抑制尿酸吸收的作用。
实施例4、高尿酸血症伴高血脂、高血糖小鼠模型建立验证
1-4周模型建立正常饲料对照组和高尿酸模型组，在第4周末，所有小鼠前一晚上禁饮食，提尾膀胱刺激法取尿、尾静脉取血、每周测量体重测血清尿酸(SUA)、尿尿酸(UUA)、甘油三脂(TG)、总胆固醇(T-CHO)、血糖(Glu)和Weight见表3。
表3、高尿酸伴高血脂高血糖建模4周，正常饲料对照组和高尿酸模型组SUA、UUA、TG、T-CHO、Glu和Weight的变化表
高尿酸模型组经4周的模型饲料饮食，第4周末前一晚上禁饮食，取尿、取血检测各指标，每周测量体重显示：MG组的SUA、UUA、TG、T-CHO、Glu和Weight显著高于BCG(P<0.05)。说明高尿酸伴高血脂高血糖小鼠建模成功。
实施例5、小鼠模型SiSLC2A9干扰初步结果验证
实验第6周尾静脉取血、取尿和每周测量体重测SUA、UUA、TG、T-CHO、Glu和Weight，实验第8周结束，各实验组小鼠摘眼球测量上述参数，测试方法与实施例4中一致。结果如图7～12所示。
0-4周动物模型建立，结果MG组的SUA、UUA、TG、T-CHO、Glu和Weight显著高于BCG(P<0.05)，说明高尿酸伴高血脂高血糖小鼠建模成功，并且MG组小鼠体重显著高于BCG组。
4-8周为各实验组不同处理疗效：SiSLC2A9显著降低血尿酸、甘油三酯、总胆固醇和血糖的水平。随着MG组小鼠模型饲料饮食时间的增加，UUA排出减少而SiSLC2A9组小鼠UUA排出增加。在体重方面MG组小鼠模型饲料饮食时间的增加，体重增加，SiSLC2A9组小鼠，体重下降。
实施例6、小鼠模型SiSLC2A9干扰最终结果验证
实验第8周结束，各实验组小鼠：
(1)检测血清肌酐Cr的含量(图13(A))、血尿素氮BUN的含量(图13(B))；取肝做肝匀浆检测黄嘌呤氧化酶XOD的变化(图13(C))；结果显示：以上3个指标BCG组低于MG组，SLC2A9组(P<0.05)，MG组高于BCG组和SLC2A9组(P<0.05),SLC2A9组低于MG组(P<0.05)高于BCG组(P<0.05)；
(2)取肾脏皮质(图14(A))和小肠回肠(图14(B))用ELISAI方法检测促炎因子L-1β的变化；结果显示：促炎因子IL-1β在肾、小肠中的含量，BCG组低于MG组，SiSLC2A9组(P<0.05)；MG组高于BCG组SiSLC2A9组(P<0.05),SiSLC2A9组低于MG组(P<0.05)高于BCG组(P<0.05)；
(3)取全小肠内容物检测小肠内容物尿酸的变化(图15)；BCG组高于MG组，SiSLC2A9组(P<0.05)，MG组低于BCG组SiSLC2A9组(P<0.05),SiSLC2A9组低于BCG组(P<0.05)高于MG组(P<0.05)；结果显示：MG组、模型饲料饮食小鼠从小肠排出尿酸减少，SiSLC2A9组小鼠小肠排尿酸增加。
(4)取肾脏皮质和小肠回肠做HE染色免疫组化检测肾脏和小肠结构的变化(图16(A)、16(B))，以及免疫组化SLC2A9蛋白质的表达变化(图17(A)、17(B))；显示在肾脏，小肠内SLC2A9蛋白质的表达：BCG组低于MG组(P<0.05)高于SiLC2A9组(P<0.05)MG组高于BCG组SiLC2A9组(P<0.05)，SiLC2A9组低BCG组，MG组(P<0.05)。
从图16(A)可以看出，HE染色肾脏结构的改变：虚线箭头指的是肾小球、肾小囊的改变，MG组显示：肾小囊腔隙增宽，囊腔内有粘液性渗出。实线箭头指的是肾小管上皮细胞及其排列紊乱程度，BCG组，显示细胞排列整齐，管腔内无液体渗出；MG组细胞排列紊乱，管腔内有液体渗出；SiSLC2A9组细胞排列整齐，管腔内有少许液体渗出。空心箭头指的是成纤维细胞，相比其他实验组，MG组有更多的成纤维细胞增生。
从图16(B)可以看出，HE染色小肠绒毛结构改变：虚线箭头是小肠上皮细胞及其排列紊乱程度，BCG组显示细胞排列整齐；MG组显示绒毛肿胀，细胞排列紊乱，可见多层排列；SiSLC2A9组细胞排列整齐。实线箭头指的是绒毛内毛细血管血流状态改变，MG组有血流状态改变。
结果说明：MG组小鼠肾、小肠有炎症；SiSLC2A9能改善由高尿酸、高血脂、高血糖所引起肾、小肠结构的改变，对肾小肠有保护作用。
综上，本发明的SiSLC2A9干扰序列：
(1)能在细胞水平降低SLC2A9基因的mRNA的转录和蛋白质的表达，减少TCMK1细胞对尿酸的吸收；
(2)模型小鼠肾脏和小肠SLC2A9蛋白质的表达增加，SiSLC2A9能降低肾小肠SLC2A9的表达；
(3)SiSLC2A9能降低高尿酸血症伴高血脂高血糖小鼠的尿酸、甘油三酯、胆固醇和血糖的水平，具有减轻体重的作用；
(4)能降低肾脏和小肠促炎因子IL-1β的含量，减少肾小肠炎症的发生；增加肾排出肌酐和尿素氮：能改善肾小肠的结构，说明干扰SiSLC2A9有保护肾和小肠作用。
当然，以上仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (1)
1.抑制GLUT-9蛋白表达的核酸物质在制备治疗高尿酸血症伴高血脂和高血糖的药品中的应用；
所述抑制GLUT-9蛋白表达的核酸物质为抑制SLC2A9基因表达的siRNA；
所述siRNA由体外合成的正义链和反义链碱基配对退火形成；
siRNA的正义链的核苷酸序列为SEQ ID NO:1，反义链的核苷酸序列为SEQ ID NO:2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110483204.5A CN113181206B (zh) | 2021-04-30 | 2021-04-30 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110483204.5A CN113181206B (zh) | 2021-04-30 | 2021-04-30 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113181206A CN113181206A (zh) | 2021-07-30 |
| CN113181206B true CN113181206B (zh) | 2023-07-14 |
Family
ID=76983387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110483204.5A Active CN113181206B (zh) | 2021-04-30 | 2021-04-30 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113181206B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038700A1 (zh) * | 2009-09-29 | 2011-04-07 | 苏州瑞博生物技术有限公司 | Fam3b基因的抑制剂和抑制剂组合物及抑制方法以及抑制剂在制药中的应用 |
| WO2019183292A1 (en) * | 2018-03-20 | 2019-09-26 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating hyperuricemia and gout |
| CN111148735A (zh) * | 2017-10-04 | 2020-05-12 | 日本烟草产业株式会社 | 含氮杂芳基化合物及其药物用途 |
| CN112451537A (zh) * | 2020-11-16 | 2021-03-09 | 武汉轻工大学 | 黄芩苷在制备预防和/或治疗无症状高尿酸血症和/或尿酸性肾病的药物中的应用 |
| CN112587573A (zh) * | 2021-01-15 | 2021-04-02 | 广西壮族自治区中医药研究院 | 壮药五叶泡醇提物作为制备抗高尿酸血症药物的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050197312A1 (en) * | 2004-03-03 | 2005-09-08 | Kevin Fitzgerald | Transcription factor RNA interference reagents and methods of use thereof |
-
2021
- 2021-04-30 CN CN202110483204.5A patent/CN113181206B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038700A1 (zh) * | 2009-09-29 | 2011-04-07 | 苏州瑞博生物技术有限公司 | Fam3b基因的抑制剂和抑制剂组合物及抑制方法以及抑制剂在制药中的应用 |
| CN111148735A (zh) * | 2017-10-04 | 2020-05-12 | 日本烟草产业株式会社 | 含氮杂芳基化合物及其药物用途 |
| WO2019183292A1 (en) * | 2018-03-20 | 2019-09-26 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating hyperuricemia and gout |
| CN112451537A (zh) * | 2020-11-16 | 2021-03-09 | 武汉轻工大学 | 黄芩苷在制备预防和/或治疗无症状高尿酸血症和/或尿酸性肾病的药物中的应用 |
| CN112587573A (zh) * | 2021-01-15 | 2021-04-02 | 广西壮族自治区中医药研究院 | 壮药五叶泡醇提物作为制备抗高尿酸血症药物的用途 |
Non-Patent Citations (2)
| Title |
|---|
| Effects of Bacillus subtilis on growth performance, serum biochemical parameters and organ development of weaned bamboo rats;Ban Bo et al.;Chinese Journal of Animal Nutrition;第33卷;第7192-7200页 * |
| 腹型肥胖与脑梗死及其TOAST分型相关性研究;张文卿;青岛大学医学院学报;第47卷;第1-4页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113181206A (zh) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | TNFα-induced up-regulation of miR-155 inhibits adipogenesis by down-regulating early adipogenic transcription factors | |
| Cha et al. | Dexras1 mediates glucocorticoid-associated adipogenesis and diet-induced obesity | |
| CN113143949B (zh) | 靶向SLC22A12基因的siRNA及其在高尿酸血症伴高血脂、高血糖治疗中的应用 | |
| Zhao et al. | MiRNA-337 leads to podocyte injury in mice with diabetic nephropathy. | |
| Shi et al. | Influence of LncRNA UCA1 on glucose metabolism in rats with diabetic nephropathy through PI3K-Akt signaling pathway. | |
| Man et al. | MiR-503 inhibits adipogenesis by targeting bone morphogenetic protein receptor 1a | |
| Zhao et al. | miR‐101‐3p contributes to the progression of preeclampsia by suppressing WDR5‐mediated proliferation and invasion of trophoblast | |
| CN113181206B (zh) | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 | |
| Wang et al. | MiR-190b impedes pancreatic β cell proliferation and insulin secretion by targeting NKX6-1 and may associate to gestational diabetes mellitus | |
| CN108660212B (zh) | Wdr1基因在制备非小细胞肺癌治疗和检测产品中的应用 | |
| US9879258B2 (en) | Treatment of insulin resistance through inhibitors of transcription factor TSC22D4 | |
| CN113913511B (zh) | Otulin在制备诊疗纤毛相关疾病试剂中的应用 | |
| Vega et al. | Elevated glucose alters global gene expression and tenascin-C alternative splicing in mesangial cells | |
| Wu et al. | Effect of Src tyrosine kinase on a rat model of asthma | |
| CN111560376B (zh) | 一种特异抑制OLFM4基因表达的siRNA及其应用 | |
| CN105087586B (zh) | 一种抑制牛MEN1基因表达的siRNAs序列及其应用 | |
| Huang et al. | LINC1810064F22Rik sequesters miR-206-5p away from HDAC4 to exacerbate allergic airway inflammation and airway remodeling in an ovalbumin mouse model of asthma | |
| CN114081895B (zh) | 一种用于治疗糖尿病性视网膜病变的miRNA及其应用 | |
| Yuan et al. | miR-30c inhibits renal fibrosis in diabetic nephropathy by down-regulating ROCK2 | |
| CN118256615A (zh) | Fgf19基因在制备检测牛乳房炎试剂或试剂盒中的应用 | |
| CN113181377A (zh) | Abcg2蛋白在制备改善、治疗或辅助治疗高尿酸血症伴高血脂、高血糖的制剂中的应用 | |
| CN116497115A (zh) | LncRNA SNHG16作为初发2型糖尿病诊断标志物的应用 | |
| Jiang et al. | Emerging Role of Kcnq1ot1/miR-381-3p/ETS2 Signaling Axis in Inflammation of Acute Respiratory Distress Syndrome | |
| CN116898975A (zh) | Ythdc1抑制剂在制备防治早产的药物中的应用 | |
| Zhang et al. | Novel insights into transfer RNA-derived small RNA (tsRNA) in cardio-metabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |